Elanco Animal Health Incorporated (NYSE:ELAN) Receives Average Rating of “Moderate Buy” from Analysts

Elanco Animal Health Incorporated (NYSE:ELAN) has received a consensus rating of “Moderate Buy” from the thirteen brokerages that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $21.5556.

A number of brokerages have recently commented on ELAN. JPMorgan Chase & Co. upgraded Elanco Animal Health from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $18.00 to $24.00 in a report on Tuesday, October 7th. Stifel Nicolaus boosted their target price on Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a research note on Wednesday, September 24th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Elanco Animal Health in a research report on Tuesday, November 25th. Wall Street Zen upgraded shares of Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 15th. Finally, Argus raised shares of Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a research report on Wednesday, November 19th.

Hedge Funds Weigh In On Elanco Animal Health

A number of large investors have recently modified their holdings of the business. SJS Investment Consulting Inc. increased its position in shares of Elanco Animal Health by 2,563.5% in the third quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock valued at $28,000 after acquiring an additional 1,333 shares during the last quarter. Huntington National Bank increased its position in shares of Elanco Animal Health by 136.7% during the 3rd quarter. Huntington National Bank now owns 1,882 shares of the company’s stock worth $38,000 after purchasing an additional 1,087 shares during the last quarter. Whittier Trust Co. of Nevada Inc. raised its stake in shares of Elanco Animal Health by 80.3% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock worth $42,000 after purchasing an additional 900 shares in the last quarter. Farther Finance Advisors LLC raised its stake in shares of Elanco Animal Health by 79.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock worth $43,000 after purchasing an additional 951 shares in the last quarter. Finally, First Horizon Advisors Inc. boosted its holdings in shares of Elanco Animal Health by 184.3% in the 2nd quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company’s stock valued at $53,000 after buying an additional 2,414 shares during the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Stock Down 0.2%

Elanco Animal Health stock opened at $23.27 on Monday. The company has a 50 day moving average of $21.32 and a 200-day moving average of $17.48. The company has a quick ratio of 1.23, a current ratio of 2.40 and a debt-to-equity ratio of 0.59. Elanco Animal Health has a twelve month low of $8.02 and a twelve month high of $23.70. The stock has a market capitalization of $11.56 billion, a PE ratio of 387.90, a price-to-earnings-growth ratio of 3.16 and a beta of 1.86.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, topping analysts’ consensus estimates of $0.13 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.09 billion. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The firm’s quarterly revenue was up 10.4% on a year-over-year basis. During the same period last year, the business posted $0.13 earnings per share. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS. Q4 2025 guidance at 0.090-0.120 EPS. On average, equities research analysts anticipate that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.